Actionable news
All posts from Actionable news
Actionable news in INCY: Incyte Corporation,

Incyte acquires rights from Eli Lilly to develop JAK inhibitor ruxolitinib for GVHD

Incyte (NASDAQ:INCY) and Eli Lilly (LLY) amend their 2009 License Agreement to enable Incyte to develop and commercialize Jakafi (ruxolitinib) for the treatment of graft-versus-host disease (GVHD). Incyte, in turn, has amended its Collaboration and License Agreement with Novartis (NYSE:NVS) granting it exclusive...